Potential antitumor activity of novel DODAC/PHO-S liposomes

References

• Ríos-MarcoPJiménez-LópezJMMarcoCSegoviaJLCarrascoMPAntitumoral alkylphospholipids induce cholesterol efflux from the plasma membrane in HepG2 cellsJ Pharmacol Exp Ther2011336386687321148684
   PubMed Web of Science ®Google Scholar
• Van BlitterswijkWJVerheijMAnticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospectsCurr Pharm Des200814212061207418691116
   PubMed Web of Science ®Google Scholar
• Van BlitterswijkWJVerheijMAnticancer mechanisms and clinical application of alkylphospholipidsBiochim Biophys Acta20131831366367423137567
   PubMed Web of Science ®Google Scholar
• FerreiraAKMenegueloRNetoSCChiericeGOMariaDASynthetic phosphoethanolamine induces apoptosis through caspase-3 pathway by decreasing expression of bax/bad protein and changes cell cycle in melanomaJ Cancer Sci Ther2011315359
   Google Scholar
• FerreiraAKMenegueloRMarquesFLSynthetic phosphoethanolamine a precursor of membrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10 and in vitro induce apoptosis and arrest in G2/M phaseBiomed Pharmacother201266754154822902646
   PubMed Web of Science ®Google Scholar
• FerreiraAKSantana-LemosBARegoEMFilhoOMChiericeGOMariaDASynthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effectsBr J Cancer2013109112819282824201752
   PubMed Web of Science ®Google Scholar
• FerreiraAKFreitasVMLevyDAnti-angiogenic and anti-metastatic activity of synthetic phosphoethanolaminePLoS One201383e5793723516420
   PubMed Web of Science ®Google Scholar
• FerreiraAKMenegueloRPereiraAMendonça FilhoOChiericeGOMariaDAAnticancer effects of synthetic phosphoethanolamine on Ehrlich ascites tumor: an experimental studyAnticancer Res20123219510422213293
   PubMed Web of Science ®Google Scholar
• Jiménez-LópezJMRíos-MarcoPMarcoCSegoviaJLCarrascoMPAlterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipidsLipids Health Dis201025933
   Google Scholar
• DorloTPBalasegaramMBeijnenJHDe VriesPJMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisJ Antimicrob Chemother201267112576259722833634
   PubMed Web of Science ®Google Scholar
• ThakurAJoshiNShanmugamTBanerjeeRProapoptotic miltefosine nanovesicles show synergism with paclitaxel: implications for glioblastoma multiforme therapyCancer Lett2013334227428322935677
   PubMed Web of Science ®Google Scholar
• OliveiraACMartensTFRaemdonckKDioctadecyldimethylammonium: monoolein nanocarriers for efficient in vitro gene silencingACS Appl Mater Interfaces2014696977698924712543
   PubMed Web of Science ®Google Scholar
• El-aneedAAn overview of current delivery systems in cancer gene therapyJ Control Release200494111414684267
   PubMed Web of Science ®Google Scholar
• Carmona-RibeiroAMBilayer-forming synthetic lipids: drugs or carriers?Curr Med Chem200310222425244614529483
   PubMed Web of Science ®Google Scholar
• ShimGKimMParkJYOhYKApplication of cationic liposomes for delivery of nucleic acidsAsian J Pharm Clin Res2013827280
   Google Scholar
• HoEARamsayEGinjMCharacterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting propertiesJ Pharm Sci20109962839285320091826
   PubMed Web of Science ®Google Scholar
• ManziniMCPerezKRRiskeKAPeptide:lipid ratio and membrane surface charge determine the mechanism of action of the antimicrobial peptide BP100. Conformational and functional studiesBiochim Biophys Acta2014183871985199924743023
   PubMed Web of Science ®Google Scholar
• AkbarzadehARezaei-SadabadyRDavaranSLiposome: classification, preparation, and applicationsNanoscale Res Lett20138110223432972
   PubMed Web of Science ®Google Scholar
• FenskeDBChonnACullisPRLiposomal nanomedicines: an emerging fieldToxicol Pathol2008361212918337218
   PubMed Web of Science ®Google Scholar
• FillionPDesjardinsASayasithKLagacéJEncapsulation of DNA in negatively charged liposomes and inhibition of bacterial gene expression with fluid liposome-encapsulated antisense oligonucleotidesBiochim Biophys Acta200115151445411597351
   PubMed Web of Science ®Google Scholar
• OliveiraTRBenattiCRLamyMTStructural characterization of the interaction of the polyene antibiotic Amphotericin B with DODAB bicelles and vesiclesBiochim Biophys Acta20111808112629263721839723
   PubMed Web of Science ®Google Scholar
• HauserHNucleic acids, peptides, and proteinsFranksFWater, a Comprehensive TreatiseNew YorkPlenum Press1975209303
   Google Scholar
• HauserHWater/phospholipid interactionsDuckworthRBWater Relations of FoodsLondonAcademic Press19753741
   Google Scholar
• FangJNakamuraHMaedaHThe EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effectAdv Drug Deliv Rev201163313615120441782
   PubMed Web of Science ®Google Scholar
• TaurinSNehoffHGreishKAnticancer nanomedicine and tumor vascular permeability; Where is the missing link?J Control Release2012164326527522800576
   PubMed Web of Science ®Google Scholar
• HyodoKYamamotoESuzukiTKikuchiHAsanoMIshiharaHDevelopment of liposomal anticancer drugsBiol Pharmaceut Bull2013365703707
   PubMed Web of Science ®Google Scholar
• OliveiraLCTaveiraEJFSouzaLGMarretoRNLimaEMTaveiraSF[Applications of lipid nanoparticles in the treatment of solid tumors: review of literature]. Aplicações das Nanopartículas Lipídicas no Tratamento de Tumores Sólidos: Revisão de LiteraturaRev Bras Cancerol2012584695701 Portugese
   Google Scholar
• TrédanOGalmariniCMPatelKTannockIFDrug resistance and the solid tumor microenvironmentJ Natl Cancer Inst200799191441145417895480
   PubMed Web of Science ®Google Scholar
• MorilleMPassiraniCVonarbourgAClavreulABenoitJPProgress in developing cationic vectors for non-viral systemic gene therapy against cancerBiomaterials20082924–253477349618499247
   PubMed Web of Science ®Google Scholar
• TokuiTTakatoriTShinozakiNDelivery and cytotoxicity of RS-1541 in St-4 human gastric cancer cells in vitro by the low-density-lipoprotein pathwayCancer Chemother Pharmacol1995361167720169
   PubMed Web of Science ®Google Scholar
• VersluisAJVan GeelPJOppelaarHVan BerkelTJBijsterboschMKReceptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in miceBr J Cancer19967445255328761365
   PubMed Web of Science ®Google Scholar
• MasquelierMVitolsSPetersonCLow-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in miceCancer Res1986468384238473731059
   PubMed Web of Science ®Google Scholar
• MouraJAValdugaCJTavaresERKretzerIFMariaDAMaranhãoRCNovel formulation of a methotrexate derivative with a lipid nanoemulsionInt J Nanomedicine2011612285229522072866
   PubMedGoogle Scholar
• ContenteTCKretzerIFFilippin-MonteiroFBMariaDAMaranhãoRCAssociation of daunorubicin to a lipid nanoemulsion that binds to low-density lipoprotein receptors enhances the antitumour action and decreases the toxicity of the drug in melanoma-bearing miceJ Pharm Pharmacol201466121698170925131262
   PubMed Web of Science ®Google Scholar
• KretzerIFMariaDAMaranhãoRCDrug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsionCell Oncol2012356451460
   Web of Science ®Google Scholar